Oct 2026· Medical Oncology· Vol 43· 0 citations· 78 references
Medicine
TL;DR
A therapeutic framework for overcoming immunotherapy resistance, which may potentially convert the metabolic vulnerabilities of cancer cells into immunological activating signals, hypothesized to drive durable anti-tumor immunity is proposed.
Ferroptosis, cuproptosis, and pyroptosis are distinct forms of programmed cell death (PCD) that are increasingly recognized as interconnected regulators of tumor progression, metabolic adaptation, and therapeutic response beyond classical apoptosis. While research into individual pathways has expanded rapidly, a cohesi...
Osteosarcoma is characterized by early metastatic potential, frequent postoperative recurrence, and resistance to conventional chemotherapy, and therapeutic progress remains limited. Osteosarcoma may have exploitable vulnerabilities due to metal homeostasis and redox control dysregulation. However, metal-associated cyt...
Xue-Hai Liu, Lin-Zhu Li, Yu-Fei Yang et al.· American Journal of Cancer R...· 0 citations
Immunotherapy has transformed cancer treatment, yet its efficacy in solid tumors remains constrained by primary or acquired resistance. Increasing evidence suggests that ferroptosis sensitivity is shaped not only by tumor intrinsic metabolic programs but also by the surrounding microenvironment. Ferroptosis, an iron-de...
Wan-Qiu Zhang, Xiao-Fei Zhang, Si-Lin Kong et al.· Cellular Reprogramming· 0 citations
Cuproptosis is a recently defined form of regulated cell death driven by disruption of intracellular copper homeostasis and is mechanistically distinct from apoptosis, ferroptosis, and other established cell-death programs. Its execution is closely linked to mitochondrial metabolism and the FDX1–protein-lipoylation mac...
Yu-Kun Zhang, Ming-Da Wu, Jie-Wang Wen et al.· Frontiers in Cell and Develo...· 0 citations
This review summarizes current understanding of the molecular mechanisms governing cuproptosis and ferroptosis and identifies unresolved questions concerning pathway specificity, temporal regulation, biomarker validation, and the clinical safety of systemic or prolonged therapeutic modulation.
Yuan-Yuan Li, F. Tay· Signal Transduction and Targ...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.